A citation-based method for searching scientific literature

Inga Plaskocinska, Hannah Shipman, James Drummond, Edward Thompson, Vanessa Buchanan, Barbara Newcombe, Charlotte Hodgkin, Elisa Barter, Paul Ridley, Rita Ng, Suzanne Miller, Adela Dann, Victoria Licence, Hayley Webb, Li Tee Tan, Margaret Daly, Sarah Ayers, Barnaby Rufford, Helena Earl, Christine Parkinson, Timothy Duncan, Mercedes Jimenez-Linan, Gurdeep S Sagoo, Stephen Abbs, Nicholas Hulbert-Williams, Paul Pharoah, Robin Crawford, James D Brenton, Marc Tischkowitz. J Med Genet 2016
Times Cited: 33







List of co-cited articles
195 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.
Angela George, Daniel Riddell, Sheila Seal, Sabrina Talukdar, Shazia Mahamdallie, Elise Ruark, Victoria Cloke, Ingrid Slade, Zoe Kemp, Martin Gore,[...]. Sci Rep 2016
94
54

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
661
36

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
835
30

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
955
30


Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
561
27

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
696
27

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
Shiyu Zhang, Robert Royer, Song Li, John R McLaughlin, Barry Rosen, Harvey A Risch, Isabel Fan, Linda Bradley, Patricia A Shaw, Steven A Narod. Gynecol Oncol 2011
237
24

Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
Maira Kentwell, Eryn Dow, Yoland Antill, C David Wrede, Orla McNally, Emily Higgs, Anne Hamilton, Sumitra Ananda, Geoffrey J Lindeman, Clare L Scott. Gynecol Oncol 2017
54
24

Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
Belinda Rahman, Anne Lanceley, Rebecca S Kristeleit, Jonathan A Ledermann, Michelle Lockley, Mary McCormack, Tim Mould, Lucy Side. J Med Genet 2019
20
40

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
21

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
656
21

Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
Nicoletta Colombo, Gloria Huang, Giovanni Scambia, Eva Chalas, Sandro Pignata, James Fiorica, Linda Van Le, Sharad Ghamande, Santiago González-Santiago, Isabel Bover,[...]. J Clin Oncol 2018
45
21

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012
357
18

The integration of BRCA testing into oncology clinics.
Natalie Percival, Angela George, Jennifer Gyertson, Monica Hamill, Andreia Fernandes, Emily Davies, Nazneen Rahman, Susana Banerjee. Br J Nurs 2016
31
19

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Lalloo. J Med Genet 2004
178
18

Inherited Mutations in Women With Ovarian Carcinoma.
Barbara M Norquist, Maria I Harrell, Mark F Brady, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Sarah S Bernards, Silvia Casadei, Qian Yi, Robert A Burger,[...]. JAMA Oncol 2016
331
18

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Angela George, Stan Kaye, Susana Banerjee. Nat Rev Clin Oncol 2017
83
18

Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
Marc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, Jeanne Mandelblatt, Rachel Nusbaum, An-Tsun Huang, Yaojen Chang, Kristi Graves, Claudine Isaacs, Marie Wood,[...]. J Clin Oncol 2014
147
15

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
480
15

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Francisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, Julie M Cunningham, Brooke L Fridley, Melissa C Larson, Kathryn Alsop, Ed Dicks, Patricia Harrington, Susan J Ramus,[...]. Clin Cancer Res 2015
90
15

Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Susan J Ramus, Honglin Song, Ed Dicks, Jonathan P Tyrer, Adam N Rosenthal, Maria P Intermaggio, Lindsay Fraser, Aleksandra Gentry-Maharaj, Jane Hayward, Susan Philpott,[...]. J Natl Cancer Inst 2015
200
15

The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.
D Gareth Evans, Julian Barwell, Diana M Eccles, Amanda Collins, Louise Izatt, Chris Jacobs, Alan Donaldson, Angela F Brady, Andrew Cuthbert, Rachel Harrison,[...]. Breast Cancer Res 2014
178
15

Identifying Needs: a Qualitative Study of women's Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study.
Mirjam Tonheim Augestad, Hildegunn Høberg-Vetti, Cathrine Bjorvatn, Ragnhild Johanne Tveit Sekse. J Genet Couns 2017
14
35

There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer.
B Meiser, M Gleeson, N Kasparian, K Barlow-Stewart, M Ryan, K Watts, D Menon, G Mitchell, K Tucker. Gynecol Oncol 2012
30
16

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
530
15

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
K Rust, P Spiliopoulou, C Y Tang, C Bell, D Stirling, Thf Phang, R Davidson, M Mackean, F Nussey, R M Glasspool,[...]. BJOG 2018
11
45

Validation of a decision regret scale.
Jamie C Brehaut, Annette M O'Connor, Timothy J Wood, Thomas F Hack, Laura Siminoff, Elisa Gordon, Deb Feldman-Stewart. Med Decis Making 2003
579
12

Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling?
Elvira M Zilliacus, Bettina Meiser, Elizabeth A Lobb, Patrick J Kelly, Kristine Barlow-Stewart, Judy A Kirk, Alan D Spigelman, Linda J Warwick, Katherine M Tucker. Genet Med 2011
41
12

A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire.
David Cella, Chanita Hughes, Amy Peterman, Chih-Hung Chang, Beth N Peshkin, Marc D Schwartz, Lari Wenzel, Amy Lemke, Alfred C Marcus, Caryn Lerman. Health Psychol 2002
162
12

Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.
Anita Y Kinney, Karin M Butler, Marc D Schwartz, Jeanne S Mandelblatt, Kenneth M Boucher, Lisa M Pappas, Amanda Gammon, Wendy Kohlmann, Sandra L Edwards, Antoinette M Stroup,[...]. J Natl Cancer Inst 2014
72
12

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
931
12

Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study.
Kelly A Metcalfe, Isabel Fan, John McLaughlin, Harvey A Risch, Barry Rosen, Joan Murphy, Linda Bradley, Susan Armel, Ping Sun, Steven A Narod. Gynecol Oncol 2009
44
12

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
315
12

Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R Frankum, Georgina Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie Snape,[...]. Nat Genet 2011
308
12

Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, Christopher J Lord, Rachael Natrajan, Radost Vatcheva, Douglas A Levine, Jeff Boyd, Jorge S Reis-Filho, Alan Ashworth. Nature 2008
636
12

Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Honglin Song, Ed Dicks, Susan J Ramus, Jonathan P Tyrer, Maria P Intermaggio, Jane Hayward, Christopher K Edlund, David Conti, Patricia Harrington, Lindsay Fraser,[...]. J Clin Oncol 2015
161
12

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
817
12

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
12

Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial.
Marijke R Wevers, Margreet G E M Ausems, Senno Verhoef, Eveline M A Bleiker, Daniela E E Hahn, Titia Brouwer, Frans B L Hogervorst, Rob B van der Luijt, Thijs van Dalen, Evert B Theunissen,[...]. Genet Med 2016
16
25

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
559
12

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
Hildegunn Høberg-Vetti, Cathrine Bjorvatn, Bent E Fiane, Turid Aas, Kathrine Woie, Helge Espelid, Tone Rusken, Hans Petter Eikesdal, Wenche Listøl, Marianne T Haavind,[...]. Eur J Hum Genet 2016
35
12

Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.
Hannah Shipman, Samantha Flynn, Carey F MacDonald-Smith, James Brenton, Robin Crawford, Marc Tischkowitz, Nicholas J Hulbert-Williams. J Genet Couns 2017
8
50

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Philipp Harter, Jan Hauke, Florian Heitz, Alexander Reuss, Stefan Kommoss, Frederik Marmé, André Heimbach, Katharina Prieske, Lisa Richters, Alexander Burges,[...]. PLoS One 2017
41
12

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
365
12

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
318
12


More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling.
Aisha S Sie, Wendy A G van Zelst-Stams, Liesbeth Spruijt, Arjen R Mensenkamp, Marjolijn J L Ligtenberg, Han G Brunner, Judith B Prins, Nicoline Hoogerbrugge. Fam Cancer 2014
30
10

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
962
9

The role of BRCA mutation testing in determining breast cancer therapy.
Alison H Trainer, Craig R Lewis, Kathy Tucker, Bettina Meiser, Michael Friedlander, Robyn L Ward. Nat Rev Clin Oncol 2010
65
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.